Multiple sclerosis, relapsing-remitting has been the subject of sustained clinical investigation across multiple research sites.

14 total trials for this combination

Showing top 10 of 14 trials

Trials

NCT ID	Title	Status	Phase
NCT00676715	A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis	COMPLETED	PHASE2
NCT00530348	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One	COMPLETED	PHASE3
NCT00206648	An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS	COMPLETED	PHASE4
NCT03500328	Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial	ACTIVE_NOT_RECRUITING	NA
NCT00050778	A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis	COMPLETED	PHASE2
NCT03535298	Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS	ACTIVE_NOT_RECRUITING	PHASE4
NCT00099502	BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients	COMPLETED	PHASE3
NCT02637856	A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)	COMPLETED	PHASE3
NCT00459667	BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose	COMPLETED	PHASE3
NCT03689972	A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration	COMPLETED	PHASE3

Related Pages

All Multiple sclerosis, relapsing-remitting trials All trials in Columbus, United States